Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac
Sponsor: Butantan Institute
Listed as NCT04456595, this PHASE3 trial focuses on COVID-19 and remains completed. Sponsored by Butantan Institute, it has been updated 10 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Mar 2023 — Mar 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Mar 2021 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Sep 2020 — Nov 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Jul 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Butantan Institute
- Sinovac Life Sciences Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barretos, Brazil , Belo Horizonte, Brazil , Brasília, Brazil , Campinas, Brazil , Campo Grande, Brazil , Cuiabá, Brazil , Curitiba, Brazil , Pelotas, Brazil , Porto Alegre, Brazil , Ribeirão Preto, Brazil and 4 more locations